

DAFTAR PUSTAKA

- Acton, J. P., 1976, Evaluating public programmes to save lives: the case of heart attacks, *Laporan Penelitian*, RAND Corporation, Santa Monica.
- Andayani, T. M., 2013, *Farmakoekonomi Prinsip Dan Metodologi*, 1st Ed Bursa Ilmu, Yogyakarta.
- Aristides, M., Chen, J. & Schulz, M., 2002, Conjoint analysis of a new chemotherapy – Willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced colorectal cancer, *Pharmacoeconomics*, **20** (11), 775-784.
- Badan Pusat Statistik, 2014, *Persentase Penduduk yang Berobat Jalan menuju Tempat Berobat di Kabupaten Kulon Progo*, <https://www.kulonprogokab.bps.go.id>, diakses 22 November 2017.
- Bobinac, A., Van Exel, N. J. A., Rutten, F. F. H. & Brouwer, W. B. F., 2010, 'Willingness To Pay For A Quality-Adjusted Life Year : the individual prespective, *Value in Health*, **13**, 1046-1055.
- Bootman, J. L., Towsend, R. J. & McGhan, W. F., 1996, *Principle of Pharmacoeconomics*, 2nd Ed, Harvey Whitney Books Company, USA.
- Cawley, J., 2006, *Contingent valuation analysis of willingness to pay to reduce childhood obesity*, <http://www.nber.org/papers/w12510>, diakses 26 Juni 2017.
- Cramer, J. A. & Spilker, B., 1998, *Quality of life and pharmacoeconomics: an introduction*, Lippincott-Raven.
- Departemen Kesehatan Republik Indonesia, 2009, *Undang-Undang Republik Indonesia Nomor 36 Tahun 2009 Tentang Kesehatan*, Departemen Kesehatan Republik Indonesia, Jakarta.
- Dinas Kependudukan & Catatan Sipil Kabupaten Kulon Progo, 2016, *Data Agregat Kependudukan Tahun 2016 Menurut Jenis Pekerjaan*, <http://www.data.dukcapil.kulonprogokab.go.id>, diakses 15 November 2017.
- Dinas Kesehatan Kabupaten Kulon Progo, 2016, *Profil Kesehatan Kabupaten Kulon Progo Tahun 2016 (Data 2015)*, Dinas Kesehatan Kabupaten Kulon Progo, Kulon Progo.
- Dinas Pendapatan Pengelolaan Keuangan dan Aset, 2015, *Klasifikasi Wilayah Kabupaten Kulon Progo*, <http://www.dpkka.jogjaprovo.go.id>, diakses 7 Juli 2017.
- DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, A.G. & Posey, L.M., 2005, *Pharmacotherapy a Pathophysiological Approach*, 4th Ed, Appleton & Lange, Stamford.
- Donaldson, C., Shackley, P. & Abdalla, M., 1997, Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited, *Health Economics*, **6**, 145–159.
- Dranitsaris, G., 1997, A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection, *Springer-Verlag*, 5: 498.

- Drummond, M. F., Sculpher, M. J., Torrance, G.W., O'Brien, B. J. & Stoddart, G. L., 2005, *Methods for the Evaluation of Health Care Programmes*, Third Ed, Oxford University Press, New York.
- Eichler, H. G., Kong, S. X., Gerth, W. C., Mavros, P. & Jönsson, B., 2004, 'Use Of Cost-Effectiveness Analysis In Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected To Emerge?', *Value In Health*, 7 (5), 518-528.
- Endarti, D., Riewpaiboon, A., Thavorncharoensap, M., Praditsitthikorn, N., Hutubessy, R. & Kristina, S. A., 2015, Evaluation of Health-Related Quality of Life Among Patients with Cervical Cancer in Indonesia, *Asian Pacific Journal of Cancer Prevention*, 3345-3350.
- Endarti, D., Andayani, T. M., Kristina, S. A. & Rokhman, M. R., 2017, Developing Instrument for Estimation of Willingness To Pay Per Quality Adjusted Life Year (WTP Per QALY) As Cost-Effectiveness Threshold in Indonesia, *ICHS*, Yogyakarta.
- Fauzi, A., 2010, *Ekonomi Sumber Daya Alam dan Lingkungan*, PT Gramedia Pustaka Utama, Jakarta.
- Fayers, P.M. & Hays, R. D., 2005, *Assessing Quality Of Life In Clinical Trials: Methodes And Practice*, Oxford University Press.
- Feriyanto, N., 2015, Dominant Economic Sectors in Kulon Progo, Gunungkidul and Bantul Regencies in Yogyakarta Special Province, *Econ. J. Emerg. Mark*, 7 (2): 94, 96.
- Fernandez, J. M., Castro, E. P., Cura-Gonzalez, M. I., Cardiel, G. A., Abaira, V., LaCruz, A. I. & Perez, S. G., 2014, Willingness to pay for a quality adjusted life year: an evaluation of attitudes toward risk and preferences, *BMC health services research*, 14, 287.
- Field, B.C., 1997, *Enviromental Economic An Introduction*, Second Edition, The McGraw-Hill Companies, Inc, Singapore.
- Galante, J., Augustovski, F., Colantonio, L., Bardach, A., Caporale, L., Marti, S. G., 2011, Estimation and Comparison of EQ-5D Health States' Utility Weights for Pneumococcal and Human Papillomavirus Diseases in Argentina, Chile and The United Kingdom, *Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcome Research*, S60-64.
- Gall-Ely, M.L., 2009, Definition, Measurement And Determinants Of The Consumer's Willingness To Pay : A Critical Synthesis And Directions For Further Research, *Recherche Et Applications En Marketing*, 24, 91-113.
- Garvey, P. R., 2001, *Implementing a Risk Management Process for a Large Scale Information System Upgrade - A Case Study*, INCOSE Insight.
- Goodman, C.S., 2014, *Introduction to Health Technology Assessment*, National Library of Medicine, United States of America.
- Grosse, S. D., 2008, Assessing cost-effectiveness in healthcare: history of the \$50,000 per QALY threshold, *Expert Rev Pharmacoecon Outcomes Res*, 8:165-178.

- Gubernur Daerah Istimewa Yogyakarta, 2017, *Keputusan Gubernur Daerah Istimewa Yogyakarta Nomor 223/KEP/2017 tentang Penetapan Upah Minimum Kabupaten/Kota tahun 2018*, Yogyakarta.
- Gyrd-Hansen, D., 2003, Willingness to pay for a QALY. *Health Econ*, **12**, 1049–1060.
- Haab, T.C. & Mc Connell, K. E., 2002, *Valuing Enviromental and Natural Resources: The Econometrics of Non-market Valuation*, Edward Elgar Publishing. Inc., United Kingdom.
- Hanley, N. & Splash, C. L., 1993, *Cost Benefit Analysis and The Environment*, Edwar Elgar Publishing Limited, England.
- Herold, D.K., 2010, Patient Willingness To Pay For A Kidney Transplantation, *American Journal Of Transplantation*, 1394-1400, Doi: 10.1111/J.1600-6143.2010.03113.X.
- Javanbakht, M., Abolhasani, F., Mashayekhi, A., Baradaran, H. R. & Jahangirinoudeh, Y., 2012, Health Related Quality of Life in Patients with Type 2 Diabetes Mellitus in Iran: A National Survey, *PLoS ONE*, 7.
- Jhita, T., Petrou, S., Gumber, A., Szczepura, A., Raymond, N. T. & Bellary, S., 2014, Etnich Difference in Health Related Quality of Life for Patients with Type 2 Diabetes, *Health and Quality of Life Outcomes*, 12: 83.
- Kementerian Kesehatan Republik Indonesia, 2013^a, *Pedoman Penerapan Kajian Farmakoekonomi*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan Republik Indonesia, 2013^b, *Peraturan Menteri Kesehatan Republik Indonesia Nomor 71 Tahun 2013 Tentang Pelayanan Kesehatan pada Jaminan Kesehatan Nasional*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- King, J. T., Tsevat, J., Lave, J.R. & Roberts, M. S., 2005, Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation, *Medical Decision Making*, **25** (6): 667-677.
- Ko, F., Frick, K.D., Tzu, J., He, M. & Congdon, N., 2012, 'Willingness To Pay For potential enhancements to A Low-Cost Cataract surgical Package in rural Southern China, *Acta ophthalmologica*, E 54-e 60, Doi:10.1111/j.1755-3768.2011.02207.X.
- Kumar, S. & Baldi, A., 2013, Pharmacoeconomics: Principles, Methods And Economic Evaluation Of Drug Therapies, *Techmed*, 2:362-369.
- Laupacis, A., Feeny, D., Detsky, A. S., 1992, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations, *CMAJ*, 146:473–481.
- Lee, Y.H., Lai, Y.H., Yueh, B, Chu P.Y., Chen. Y.J., Chen S.C. & Wang, C.P., 2017, Validation of the University of Washington quality of life Chinese version (UWQOL-C) for head and neck cancer patients in Taiwan, *Journal of the Formosan medical association*, **116**, 249-256.

- Lemenhow, S., Hosmer, D.W., Klar, J. & Lwanga, S.K, 1990, *Adequacy of sample size in health studies*, World Health Organization cit. Pramono, D dan Kusnanto, H., 1997, *Besar sampel dalam penelitian kesehatan*, Gadjah Mada University Press, Yogyakarta.
- Liem, Y. S., Bosch, J. L. & Myriam, H. M. G., 2008, Preference-Based Quality of Life of Patients on Renal Replacement Therapy: A Systematic Review and Meta-Analysis, *Value in Health*, 11: 733-741.
- Lloyd, A., McIntosh, E. & Price, M., 2005, The importance of drug adverse effects compared with seizure control for people with epilepsy: A discrete choice experiment, *Pharmacoeconomics*, **23** (11), 1167-1181.
- Marseille, E., Larson, B., Kazi, D.S., Kahn, J.G. & Rosen, S., 2015, Thresholds for the cost-effectiveness of interventions: alternative approaches, *Bulletin of the World Health Organization*, **93**(2):118-124.
- Mataria, A., Giacaman, R., Khatib, R. & Moatti, J. P., 2006, Impoverishment and patients' "willingness" and "ability" to pay for improving the quality of health care in Palestine: an assessment using the contingent valuation method, *Health Policy*, **75**, 312-328.
- McCabe, C., Claxton, .K. & Culyer, A. J., 2008, The NICE cost-effectiveness threshold: what it is and what that means, *Pharmacoeconomics*, 26:733-744.
- Nimdet, K., Chaiyakunapruk, N., Vichansavakul, K. & Ngorsuraches, S., 2015, 'A Systematic Review Of Studies Eliciting Willingness-To-Pay Per Quality-Adjusted Life Year: Does It Justify Ce Threshold?', *Plos One*, **10** (4), E0122760.
- Orion, 1997, *Pharmacoeconomics Primer and Guide Introduction to Economic Evaluation*, Hoesch Marion Rousell Incorporation, Virginia.
- Owens, D.K., 1998, Interpretation of cost-effectiveness analyses, *Journal of General Internal Medicine*, **13**(10): 716.
- Pattanaphesaj, J., 2014, Health-Related Quality Of Life Measure (EQ-5D-5L): Measurement Property Testing And Its Preference-Based Score In Thai Population, Doctoral *Dissertation*, Mahidol University, Thailand.
- Purba, F. D. *et al.*, 2017, The Indonesian EQ-5D-5L Value Set, *Pharmacoeconomics*, DOI 10.1007/s40273-017-0538-9.
- Rabin, R. & Charro, F., 2001, EQ-5D: A Measure of Health Status from the EuroQol Group, *Ann Med*, 33, 337-343.
- Rabin, R., Oemar, M., Oppe, M., Janssen, B. & Herdman, M., 2011, EQ-5D-5L User Guide: Basic Information On How To Use The EQ-5D-5L Instrument, *Rotterdam Euroqol Group*, 22.
- Rascati, K., 2013, *Essential Of Pharmacoeconomics*, Lippincott Williams & Wilkins.
- Reenen, M. & Janssen, B., 2015, *EQ-5D-5L User Guide: Basic Information on How to Use the EQ-5D-5L Instrument*, EuroQol Group.
- Robinson, A., Gyrd-Hansen, D., Bacon, P., Baker, R., Pennington, M., Donaldson, C. & EuroVaQ Team, 2013, Estimating a WTP-based value of a QALY: The 'chained' approach, *Elsevier*, 92: 98.

- Ross, K. N., 2005, *Sample Design for Educational Survey Research Module 3*, International Institute for Educational Planning UNESCO, Paris.
- Sanchez, L.A., 2005, Pharmacoeconomics: Principles, Methods, And Applications, dalam: DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M. (Eds.), *Pharmacotherapy : A Pathophysiologic Approach*, McGraw-Hill, United State of America.
- Shafie, A.A. & Hassali, M.A., 2010, Willingness to pay for a pharmacist's dispensing services: A cross-sectional pilot studi in the state of Penang, Malaysia, *Pharmacy practice*, **8**, 116-121.
- Shafie, A. A., Lim, Y. W., Chua, G. N., Azmi, M. & Hassali, A., 2014, Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia, *Clinic economics and outcomes research*, (6) 473-481.
- Shiroiwa, T., Sung, Y. K. & Fukuda, T., 2010, International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?, *Health Econ*, **19**, 422–437.
- Shiroiwa, T., Igarashi, A., Fukuda, T. & Ikeda, S., 2013, WTP for a QALY and health states: More money for severer health states?, *Cost Eff Resour Alloc*, 11: 22, doi: 10.1186/1478-7547-11-22 PMID: 24128004.
- Suparmoko, M., Sudirman, D., Setyarko, Y. & Wibowo, H. S., 2014, *Valuasi Ekonomi Sumberdaya Alam dan Lingkungan*, BPFE Yogyakarta.
- Thavorncharoensap, M., Teerawattananon, Y., Natanant, S., Kulpeng, W., Yothasamut, J. & Werayingyong, P, 2013, Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?, *ClinicoEconomics and Outcomes Research*, **5**, 29-36.
- Thavorncharoensap, M., 2014, Measurement Of Utility, *J Med Assoc Thai*, **97**: S43-S49.
- Tjandrawinata, R.R., 2000, *Pharmacoeconomics to Its Basics Principles*, Dexa Medica, Jakarta.
- Tjiptoherijanto, P. & Soesetyo, B., 1994. *Ekonomi Kesehatan*, Penerbit Rhineka Cipta, Jakarta.
- Vallejo-Torres, L., García-Lorenzo, B., Castilla, I., Valcárcel-Nazco, C., García-Pérez, L., Linertová, R., Polentinos-Castro, E. & Serrano-Aguilar, P., 2016, 'On The Estimation Of The Cost-Effectiveness Threshold: Why, What, How?', *Value In Health*.
- Vogenberg, F.R., 2001, *Introduction To Applied Pharmacoeconomics*. Editor: Zollo S., McGraw-Hill Companies, USA.
- Von Stackelberg, K. & Hammitt, J., 2009, 'Use Of Contingent Valuation To Elicit Willingness-To-Pay For The Benefits Of Developmental Health Risk Reductions', *Environmental And Resource Economics*, **43** (1), 45-61.
- Wedgwood, A. & Sansom, K., 2003, *Willingness To Pay Surveys – A Streamlined Approach- Guidance Notes For Small Town Water Services*, Wedc Loughborough University, United Kingdom.

- Weinstein, M. C., 2008, How much are Americans willing to pay for a quality-adjusted life year?, *Med Care*, 46: 343–345.
- Weston, A. & FitzGerald, P., 2004, Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma, *PharmacoEconomics*, 22 (18), 1195-1208.
- Wetering, L. V. D., Exel, J. V., Bobinac, A. & Brouwer, W. B. F., 2015, Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment, *PharmacoEconomics*, 33: 1290.
- Whitehead, S.J. & Ali, S., 2010, Health outcomes in economic evaluation: the QALY and utilities, *British Medical Bulletin*, 96 (1): 5-21.
- Wilson, J. P. & Rascati, K. L., 2001, *Pharmacoeconomics, dalam Malone, Patrick M., Kier, Karen L., and Stanovich, J. E., Drug Information, 2nd Ed.*, McGraw-Hill, New York.
- World Health Organization, 2005, *Choosing Intervention that are Cost Effective (WHO-CHOICE)* World Health Organization, http://www.who.int/choice/costs/CER_thresholds/en/index.html, diakses 10 Juli 2017.
- Yamane, T., 1967, *Statistics: An Introductory Analysis*, 2nd Ed, Harper & Row, New York.
- Yeung, R.Y.T, Smith, R.D., Ho, L., Johnston, J.M. & Leung, G.M. 2006, Empirical implications of response acquiescence in discrete-choice contingent valuation, *Health Economics*, 15, 1077-1089.
- Zethraeus, N. & Johansson, P., 1997, *Willingness to pay for hormone replacement therapy*, Department of Economics, Stockholm School of Economics, Stockholm.
- Zhao, F. L., Yue, M., Yang, H., Wang, T., Wu, J. H. & Li, S. C., 2011, Willingness to pay per quality adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis, *Med Care*, 49, 267–272.